



Council

David R. Sibley
President
Bethesda, Maryland

John D. Schuetz
President-Elect
St. Jude Children's Research Hospital

Kenneth E. Thummel
Past President
University of Washington

Charles P. France
Secretary/Treasurer
The University of Texas Health
Science Center at San Antonio

John J. Tesmer
Secretary/Treasurer-Elect
University of Michigan

Dennis C. Marshall
Past Secretary/Treasurer
Ferring Pharmaceuticals, Inc.

Margaret E. Gnegy
Councilor
University of Michigan Medical School

Wayne L. Backes
Councilor
Louisiana State University Health
Sciences Center

Carol L. Beck
Councilor
Thomas Jefferson University

Mary E. Vore
Chair, Board of Publications Trustees
University of Kentucky

Brian M. Cox
FASEB Board Representative
Bethesda, Maryland

Scott A. Waldman
Chair, Program Committee
Thomas Jefferson University

Judith A. Siuciak
Executive Officer

For Immediate Release
Contact: Susanna Aguirre
301-634-7062
saguirre@aspnet.org

ASPET Applauds Passage of 21st Century Cures Act as Additional Investment in Biomedical Research

BETHESDA –The American Society for Pharmacology and Experimental Therapeutics (ASPET) commends legislators and President Obama for the final passage of the 21st Century Cures Act, which has now been signed into law.

We commend legislators for their bipartisan, bicameral support and vision in recognizing the critical importance of funding for medical research as a national priority. In particular, we are deeply grateful for the provision providing \$4.8 billion over ten years in new funding for the National Institutes of Health (NIH) and \$500 million for the Food and Drug Administration (FDA).

“The passage of this legislation is a victory for the biomedical research community, not just within the United States, but world-wide, and will have a significant impact on public health. We look forward to continued support from legislators in the appropriations process,” said Dr. David Sibley, ASPET President.

NIH’s contribution to the well-being and health of its citizens is a critical investment for the nation that will yield far greater returns through new discoveries and therapies.

With enhanced and sustained funding, NIH can continue to address the most promising scientific opportunities and critical healthcare needs of our country.

ASPET is 5,000 member scientific society whose members conduct basic and clinical pharmacological research and work for academia, government, large pharmaceutical companies, small biotech companies, and even non-profit organizations. ASPET members work in a variety of different fields and include neuroscientists, toxicologists, chemical biologists, pharmacists, cardiovascular scientists, and many more. These research efforts help develop new medicines and therapeutic agents to fight existing and emerging diseases.